ATYR
USDaTyr Pharma Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$5.550
Максимум
$5.749
Минимум
$5.330
Объем
2.00M
Фундаментальные показатели компании
Рыночная капитализация
480.2M
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
1.63M
Биржа
NCM
Валюта
USD
52-недельный диапазон
Связанные новости
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.